October, 2013: Dear Patients, Caregivers, and Friends of the Bing Center for WM: It gives me great pleasure to introduce to you two outstanding individuals who recently joined the Bing Center for Waldenstrom’s Macroglobulinemia at the Dana Farber Cancer Institute. Many of you have had the opportunity to meet Sandra Kanan, NP and Jorge Castillo, MD, during your recent clinic visits, and I wanted to take the opportunity to formally introduce you to these bright, talented, and dedicated practitioners who will soon be leading the Waldenstrom’s clinical effort for our center. Both individuals were recruited to our center, after national searches, in an effort to increase our capacity to care for a rapidly growing patient population. Over 1,000 patients with WM are expected to be seen this year, with representation from all over the globe. The increased visitations have been prompted by the discovery of the mutation in the MYD88 gene in WM which was discovered by the dedicated laboratory researchers of our center and reported in the New England Journal of Medicine last year. The discovery of the MYD88 mutation prompted research efforts that now have unveiled new opportunities for targeted therapy of WM, including the use of ibrutinib, an inhibitor of Bruton’s Tyrosine Kinase (BTK) which is activated by the MYD88 mutation.
December 7-10, 2013, New Orleans - Researchers from the Bing Center for WM attended the 2013 Annual ASH Meeting and Exposition, which was held at the Morial Convention Center. There they presented 5 posters including continued findings from the first whole genome sequencing project for WM, and continuing investigations into the MYD88 signaling pathway, L265P Mutation, CXCR4 and its effects on Ibrutinib, and a multi-center study of RAD001.
April 21, 2013: Dr. Steven Treon delivered a lecture to the New England Support Group on Genomic and Clinical Advances in Waldenstrom's Macroglobulinemia. This lecture was given at the Jimmy Fund Auditorium, Dana-Farber Cancer Institute, Boston, MA. Click here to view the lecture in its entirety.
The WM Macroglobulinemia Clinic at the DFCI is devoted to the care of patients with Waldenstrom's Macroglobulinemia and related IgM disorders, including IgM MGUS, Myeloma and Neuropathies.
Plasma cell regulatory pathways in WM. In recent studies, we have attempted to dissect the molecular mechanisms which prevent WM cells from fully differentiating into plasma cells. Ordinarily, B-cells mature in a defined manner passing through the mature B-cell stage to lymphoplasmacytic cells, and then onto mature plasma cells. Mature plasma cells make antibodies that serve to protect us against pathogens, and typically include the IgA and IgG antibodies.